Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Year: 2024
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.23.01960
Authors: Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, Lance Pagliaro, Josef Mardiak, Lionnel Geoffrois, Brigitte Laguerre, Christine Chevreau, Remy Delva, Frederic Rolland, Christine Theodore, Guilhem Roubaud, Gwenaëlle Gravis, Jean-Christophe Eymard, Mathilde Cancel, Beata Juzyna, Maria Reckova, Natacha Naoun, Christopher Logothetis, Stephane Culine
Institutions: Université Paris-Saclay, Institut Gustave Roussy, Centre de recherche en Epidémiologie et Santé des Populations, Centre Léon Bérard, The University of Texas MD Anderson Cancer Center, Centre Eugène Marquis, Institut Claudius Regaud, Institut de Cancérologie de l'Ouest, Hôpital Foch, Institut Bergonié, Institut Paoli-Calmettes, Institut Jean Godinot, Centre Hospitalier Universitaire de Tours, UniCancer Group, Hôpital Saint-Louis
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401730301